Compound: Lucitanib
SMILES: O=C(NC)c1c2c(cc(Oc3c4c(ncc3)cc(OCC5(N)CC5)c(c4)OC)cc2)ccc1
InChIKey: CUDVHEFYRIWYQD-UHFFFAOYSA-N
Synonyms: Lucitanib, 1058137-23-7, E-3810, E-3810 amine, PP449XA4BH, AL-3810, CO-3810, 6-({7-[(1-Aminocyclopropyl)methoxy]-6-Methoxyquinolin-4-Yl}oxy)-N-Methylnaphthalene-1-Carboxamide, 6-[7-[(1-aminocyclopropyl)methoxy]-6-methoxyquinolin-4-yl]oxy-N-methylnaphthalene-1-carboxamide, DTXSID30147356, S80881, S-80881, 1-Naphthalenecarboxamide, 6-((7-((1-aminocyclopropyl)methoxy)-6-methoxy-4-quinolinyl)oxy)-n-methyl-, 6-((7-((1-Aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yl)oxy)-n-methylnaphthalene-1-carboxamide, CHEBI:65138, AL3810, lucitanibum, 6-(7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yl)oxy-N-methylnaphthalene-1-carboxamide, RefChem:924964, DTXCID9069847, 6-((7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yl)oxy)-N-methyl-1-naphthamide, E-3810 free base, 6-({7-[(1-aminocyclopropyl)methoxy]-6-methoxyquinolin-4-yl}oxy)-N-methyl-1-naphthamide, CHEMBL2180605, Lucitanib [INN], 6-[[7-[(1-aminocyclopropyl)methoxy]-6-methoxy-4-quinolyl]oxy]-N-methyl-naphthalene-1-carboxamide, Lucitanib [USAN:INN], UNII-PP449XA4BH, Lucitanib(E3810), E-3810; Lucitanib, Lucitanib (USAN/INN), LUCITANIB [USAN], LUCITANIB [WHO-DD], SCHEMBL381394, GTPL7649, orb1308358, CHEMBL2220486, SCHEMBL29363689, SCHEMBL29365836, SCHEMBL29375046, CHEBI:65209, CUDVHEFYRIWYQD-UHFFFAOYSA-N, GLXC-90358, EX-A2052, BDBM50399539, EBC-13042, MFCD09607817, NSC782762, NSC800786, AKOS030526232, CS-0782, DB11845, NSC-782762, NSC-800786, SB16928, 6-(7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl-1-naphthamide, NCGC00378878-02, NCGC00378878-03, AC-35833, AS-82279, DA-33429, HY-15391, NS00072983, D11762, F84836, EN300-23251017, S 80881, BRD-K31309378-001-01-5, Q27082198, 6-(7-((1-aminocyclopropyl)methoxy)-6-methoxy-quinolin-4-yloxy)-N-methyl-1-naphthamide, 3ZC
Theoretical properties:
molecular_formula: C26H25N3O4
molecular_weight: 443.5 g/mol
exact_mass: 443.18450629 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 2
hydrogen_bond_acceptor_count: 6
rotatable_bond_count: 7
heavy_atom_count: 33
topological_polar_surface_area: 95.7 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
pubchem: E-3810 free base is a naphthalenecarboxamide obtained from formal condensation of the carboxy group of aminocyclopropyl)methoxy]-6-methoxyquinolin-4-yl}oxy)-1-naphthoic acid with methylamine. It has a role as an antineoplastic agent, a fibroblast growth factor receptor antagonist and a vascular endothelial growth factor receptor antagonist. It is a member of quinolines, an aromatic ether, a naphthalenecarboxamide, a primary amino compound and a member of cyclopropanes. It is a conjugate base of an E-3810(1+).
chebi: A naphthalenecarboxamide obtained from formal condensation of the carboxy group of aminocyclopropyl)methoxy]-6-methoxyquinolin-4-yl}oxy)-1-naphthoic acid with methylamine.
chembl: LUCITANIB is a small molecule listed in the ChEMBL database and has reached clinical trial phase 2.0.
wikipedia: Lucitanib (INN) is a drug that is being investigated by Clovis Oncology in clinical trials for the treatment of advanced solid tumours including metastatic breast cancer. It is a protein kinase inhibitor that blocks the VEGF receptors 1, 2 and 3, as well as the fibroblast growth factor receptors 1 and 2, and the platelet-derived growth factor receptors alpha and beta.